KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $426.9 million.

  • Biomarin Pharmaceutical's Income from Continuing Operations fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Income from Continuing Operations stood at $426.9 million for FY2024, which was up 154.62% from $167.6 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Income from Continuing Operations ranged from a high of $854.0 million in FY2020 and a low of -$64.1 million during FY2021.
  • Its 3-year average for Income from Continuing Operations is $245.4 million, with a median of $167.6 million in 2023.
  • In the last 5 years, Biomarin Pharmaceutical's Income from Continuing Operations skyrocketed by 3,681.13% in 2020 and then plummeted by 107.50% in 2021.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Income from Continuing Operations stood at $854.0 million in 2020, then plummeted by 107.50% to -$64.1 million in 2021, then surged by 320.91% to $141.6 million in 2022, then increased by 18.43% to $167.6 million in 2023, then surged by 154.62% to $426.9 million in 2024.